Top 5 Articles of the Month: September 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

1. French Survey Highlights Gaps in Chronic Hand Eczema Care

Chronic hand eczema (CHE) is one of the most common occupational skin diseases, yet French clinicians face the challenge of managing it without national treatment guidelines. The CHEMIN survey, which gathered insights from 135 dermatologists, allergists, and occupational health physicians, reveals striking variability in therapeutic strategies and frequent departures from European recommendations. From heavy reliance on topical corticosteroids to diverse use of systemic and biologic therapies, the findings highlight both the complexity of care and the pressing need for standardized, patient-centered treatment pathways in France.

2. EADV 2025: Full Congress Recap

At EADV 2025 in Paris, France, dermatology researchers presented a wide array of advances spanning inflammatory disease, biologics, novel therapies, and quality-of-life data. Key highlights included promising results for roxatinlimab (anti-OX40) in atopic dermatitis, sustained efficacy of bimekizumab in psoriasis out to 4 years, and early success with oral STAT6 degrader KT-621, which showed biomarker changes comparable to dupilumab. Other notable findings included new data on ruxolitinib cream in prurigo nodularis, delgocitinib cream in adolescent hand eczema, and several oral and biologic options showing durability across psoriasis, hidradenitis suppurativa, and urticaria subtypes.

3. ICYMI: DermaRite Recall Due to Sepsis Risk Expands to Creams, Hair Products

DermaRite Industries has expanded its voluntary recall to include a wide range of skin creams, soaps, sanitizers, and hair products after discovering potential contamination with Burkholderia cepacia complex, a bacterium that can cause serious, sometimes life-threatening infections—particularly in immunocompromised individuals. Sold nationwide through major retailers such as Amazon, Target, and Walmart, the recalled products include popular items like DermaCerin, Gel Rite, and Lantiseptic. Consumers are urged to stop using the affected products immediately, consult a healthcare provider if adverse effects occur, and report incidents to the FDA’s MedWatch program.

4. Johnson & Johnson Seeks EMA Approval for Oral IL-23 Antagonist Icotrokinra

Johnson & Johnson has submitted a marketing authorization application to the EMA for icotrokinra, a first-in-class oral IL-23 receptor antagonist developed with Protagonist Therapeutics. Targeting moderate to severe plaque psoriasis in adults and adolescents, icotrokinra demonstrated strong efficacy and a favorable safety profile across four phase 3 trials, showing superiority over both placebo and the oral TYK2 inhibitor deucravacitinib. If approved, it would become the first oral therapy of its kind in Europe, offering patients a once-daily tablet option that could simplify treatment while delivering high rates of skin clearance—even in difficult-to-treat areas.

5. New Consensus Defines Remission in Plaque Psoriasis to Standardize Care

A new consensus statement published in JAMA Dermatology has established the first standardized definition of on-treatment remission in plaque psoriasis: maintaining 0% body surface area involvement or an Investigator Global Assessment score of 0 for at least 6 months while continuing therapy. Developed through a multistage Delphi process led by the National Psoriasis Foundation, the definition reflects input from clinicians, researchers, payers, and patients. Experts say this benchmark will help unify treatment goals, improve patient care, and provide a consistent framework for evaluating therapies in both clinical practice and research.